Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E MAP2K1 G128V |
| Therapy | Dabrafenib + Trametinib |
| Indication/Tumor Type | melanoma |
| Response Type | conflicting |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E MAP2K1 G128V | melanoma | conflicting | Dabrafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128V in culture (PMID: 36442478). | 36442478 |
| BRAF V600E MAP2K1 G128V | melanoma | conflicting | Dabrafenib + Trametinib | Preclinical | Actionable | In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154). | 24265154 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24265154) | MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. | Full reference... |
| (36442478) | High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer. | Full reference... |